OrthoPediatrics Corp. (NASDAQ:KIDS) Receives $24.44 Consensus Target Price from Analysts

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have received a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $24.4444.

Several research firms have weighed in on KIDS. Truist Financial set a $17.00 price objective on OrthoPediatrics in a report on Friday, May 1st. Canaccord Genuity Group set a $25.00 price objective on OrthoPediatrics in a report on Friday, April 24th. Needham & Company LLC increased their price objective on OrthoPediatrics from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, February 27th. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a report on Monday. Finally, BTIG Research reiterated a “buy” rating and issued a $24.00 price objective on shares of OrthoPediatrics in a report on Friday, May 1st.

OrthoPediatrics Price Performance

KIDS opened at $18.53 on Friday. The stock’s 50 day simple moving average is $17.21 and its 200 day simple moving average is $17.42. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.21 and a quick ratio of 2.37. OrthoPediatrics has a 1 year low of $14.42 and a 1 year high of $23.70. The firm has a market cap of $475.94 million, a price-to-earnings ratio of -11.03 and a beta of 1.03.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.04. OrthoPediatrics had a negative return on equity of 7.01% and a negative net margin of 16.31%.The business had revenue of $59.36 million for the quarter, compared to analyst estimates of $58.29 million. As a group, analysts predict that OrthoPediatrics will post -1.13 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of OrthoPediatrics by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after purchasing an additional 645 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after purchasing an additional 1,139 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after purchasing an additional 1,235 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in shares of OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after purchasing an additional 2,561 shares during the period. Finally, Barclays PLC lifted its stake in shares of OrthoPediatrics by 10.7% in the 4th quarter. Barclays PLC now owns 26,405 shares of the company’s stock valued at $469,000 after purchasing an additional 2,561 shares during the period. Hedge funds and other institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.